Table 1.
Genomic aberrations and targeted genes observed in CLL patients resistant to fludarabine.
| Genomic aberrations | Type of aberration | Targeted gene(s) |
|---|---|---|
| idic(3q) | Deletion 3p | XPC, RAD18, PCAF |
| Gain 3q | BCL6, FAIM, p63 | |
| 7q21, 7q36 1 | Gain | MDR family genes |
| idic(8q) | Deletion 8p | TNFRSF10 family genes |
| Gain 8q | MYC | |
| 9p24p21 2 | Deletion | JAK2, p16INK4, CDKN2B, SMARCA2 |
| 11q23 | Deletion | ATM |
| 12p13.31p12 | Deletion | p27 |
| 13q14.2q14.3 | Deletion | DLEU genes, Rb, miR-15a, miR-16-1 |
| 15q15q26 | Gain | MGA, PML, BLM, cyclin B2, and 53BP1 |
| idic(17q) | Deletion 17p | p53, MNT |
| Gain 17q | STAT3, SPOP, RAD51L3, RARA, RDM1 |
1 These aberrations were observed only in patient CLL-6R
2 This aberration was observed only in patient CLL-3R